Mitchell J D, Lee R, Hodakowski G T, Neya K, Harringer W, Valeri C R, Vlahakes G J
Department of Surgery, Massachusetts General Hospital, Boston 02114-2696.
J Thorac Cardiovasc Surg. 1994 Jun;107(6):1481-8.
Postoperative pericardial adhesions complicate reoperative cardiac procedures. Topical application of solutions containing hyaluronic acid have been shown to reduce adhesions after abdominal and orthopedic surgery. The mechanism by which hyaluronic acid solutions prevent adhesion formation is unknown but may be due to a cytoprotective effect on mesothelial surfaces, which would limit intraoperative injury. In this study, we tested the efficacy and safety of hyaluronic acid coating solutions for the prevention of postoperative intrapericardial adhesion formation. Eighteen mongrel dogs underwent median sternotomy and pericardiotomy followed by a standardized 2-hour protocol of forced warm air desiccation and abrasion of the pericardial and epicardial surfaces. Group 1 (n = 6) served as untreated control animals. Group 2 (n = 6) received topical administration of 0.4% hyaluronic acid in phosphate-buffered saline solution at the time of pericardiotomy, at 20-minute intervals during the desiccation/abrasion protocol, and at pericardial closure. The total test dose was less than 1% of the circulating blood volume. Group 3 (n = 6) served as a vehicle control, receiving phosphate-buffered saline solution as a topical agent in a fashion identical to that used in group 2. At resternotomy 8 weeks after the initial operation, the intrapericardial adhesions were graded on a 0 to 4 severity scale at seven different areas covering the ventricular, atrial, and great vessel surfaces. In both the untreated control (group 1, mean score 3.2 +/- 0.4) and vehicle control (group 3, mean score 3.3 +/- 0.2) animals, dense adhesions were encountered. In contrast, animals treated with the hyaluronic acid solution (group 2, mean score 0.8 +/- 0.3) characteristically had no adhesions or filmy, transparent adhesions graded significantly less severe than either the untreated control (group 2 versus group 1, p < 0.001) or vehicle control (group 2 versus group 3, p < 0.001) animals. In separate experiments, six baboons were infused with 0.4% hyaluronic acid in phosphate-buffered saline solution in volumes equivalent to 2.5%, 5%, and 10% of the measured circulating blood volume. The 2.5% and 5% infusions had no effect on the parameters measured; infusion of the 10% volume produced transient hemodynamic, coagulation, and gas exchange abnormalities. Hyaluronic acid solutions are efficacious in the prevention of pericardial adhesions in this model, and they appear safe in doses five times the amount needed to prevent adhesions. Further studies investigating the mechanism by which these solutions prevent adhesions, their optimal dose and method of application, and documentation of their safe use in humans are warranted.
术后心包粘连会使再次心脏手术变得复杂。已证明局部应用含透明质酸的溶液可减少腹部和骨科手术后的粘连。透明质酸溶液预防粘连形成的机制尚不清楚,但可能是由于对间皮表面的细胞保护作用,这会限制术中损伤。在本研究中,我们测试了透明质酸涂层溶液预防术后心包内粘连形成的有效性和安全性。18只杂种犬接受正中胸骨切开术和心包切开术,随后进行标准化的2小时方案,即对心包和心外膜表面进行强制热风干燥和摩擦。第1组(n = 6)作为未治疗的对照动物。第2组(n = 6)在心包切开时、干燥/摩擦方案期间每隔20分钟以及心包关闭时局部给予磷酸盐缓冲盐溶液中的0.4%透明质酸。总测试剂量小于循环血容量的1%。第3组(n = 6)作为赋形剂对照,以与第2组相同的方式接受磷酸盐缓冲盐溶液作为局部用药。在初次手术后8周再次开胸时,在覆盖心室、心房和大血管表面的七个不同区域,根据0至4的严重程度对心包内粘连进行分级。在未治疗的对照动物(第1组,平均评分3.2 +/- 0.4)和赋形剂对照动物(第3组,平均评分3.3 +/- 0.2)中,均遇到了致密粘连。相比之下,用透明质酸溶液治疗的动物(第2组,平均评分0.8 +/- 0.3)通常没有粘连或仅有薄膜状、透明的粘连,其分级明显轻于未治疗的对照动物(第2组与第1组比较,p < 0.001)或赋形剂对照动物(第2组与第3组比较,p < 0.001)。在单独的实验中,给6只狒狒输注磷酸盐缓冲盐溶液中的0.4%透明质酸,输注量相当于所测循环血容量的2.5%、5%和10%。2.5%和5%的输注量对所测参数没有影响;输注10%的量会产生短暂的血流动力学、凝血和气体交换异常。透明质酸溶液在该模型中可有效预防心包粘连,并且在预防粘连所需剂量的五倍剂量下似乎是安全 的。有必要进一步研究这些溶液预防粘连的机制、其最佳剂量和应用方法以及在人体安全使用的记录。